Spasticity is usually caused by damage to the parts of the brain or spinal cord that control voluntary movement,?leading to a change in the balance of signals between the nervous system and the muscles, which results in increased activity in the muscles.2,3 When injected into specific muscles of people living with movement disorders, BoNT injections cause temporary muscle relaxation, which can ease symptoms and aid rehabilitation.4 BoNT-A injections are considered as a recommended first-line treatment for adults living with spasticity in several countries, including the U.S.5
Ipsen analyzed data from two large
A total of 4,974,859 records were accessed in the MarketScan database, and 10,685,964 records in the IQVIA database.1
Spasticity was identified from the two sources using International Classification of Disease (ICD) codes for spastic conditions (e.g., monoplegia, diplegia, hemiplegia and contracture).1
This revealed 126,465 and 1,151,127 people living with spasticity in the MarketScan and IQVIA databases, respectively.1
In the MarketScan database, only 5,111 people living with spasticity (4%) were treated with BoNT-A. In the IQVIA database, an even smaller percentage were treated with BoNT-A (31,176 patients, 3%).1
'We need to address barriers to treatment and find innovative ways to address the access issues in the treatment of this debilitating condition,' said Dr.
'At Ipsen, we are fully committed to improving health outcomes for people living with debilitating neurological disorders,' said Dr. Andreas Lysandropoulos, Vice President, Head of Global Medical Affairs Neuroscience at Ipsen. 'Poor control of spasticity can result in the breakthrough of painful symptoms such as muscle stiffness, spasms and involuntary contractions, which means the person living with spasticity may find it difficult to walk or perform certain tasks. These data show there is an urgent need to build on these findings and gather further insights into the underlying reasons for this disconnect.'
Follow Ipsen on Twitter via @IpsenGroup and keep up to date with ISPRM 2021 news and updates by using the hashtag #ISPRM2021
Contact:
T: 1-800-367-5690
(C) 2021 Electronic News Publishing, source